Israel Englander’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35.5M | Sell |
8,525,919
-888,373
| -9% | -$3.38M | 0.01% | 1146 |
|
|
2026
Q1 | $33M | Buy |
9,414,292
+2,828,760
| +43% | +$9.05M | 0.01% | 1147 |
|
|
2025
Q4 | $18M | Buy |
6,585,532
+2,172,081
| +49% | +$5.02M | 0.01% | 1679 |
|
|
2025
Q3 | $9.58M | Sell |
4,413,451
-4,916,772
| -53% | -$11.6M | ﹤0.01% | 2431 |
|
|
2025
Q2 | $16M | Buy |
9,330,223
+9,171,900
| +5,793% | +$22.8M | 0.01% | 1802 |
|
|
2025
Q1 | $527K | Buy |
158,323
+82,829
| +110% | +$427K | ﹤0.01% | 4775 |
|
|
2024
Q4 | $559K | Sell |
75,494
-75,445
| -50% | -$699K | ﹤0.01% | 4661 |
|
|
2024
Q3 | $1.42M | Sell |
150,939
-15,210
| -9% | -$144K | ﹤0.01% | 3999 |
|
|
2024
Q2 | $1.33M | Sell |
166,149
-1,450,712
| -90% | -$15.5M | ﹤0.01% | 3880 |
|
|
2024
Q1 | $24M | Buy |
1,616,861
+677,315
| +72% | +$7.88M | 0.01% | 1415 |
|
|
2023
Q4 | $7.64M | Sell |
939,546
-6,880,528
| -88% | -$36M | ﹤0.01% | 2418 |
|
|
2023
Q3 | $35.6M | Buy |
7,820,074
+4,239,406
| +118% | +$27.7M | 0.02% | 946 |
|
|
2023
Q2 | $25.2M | Buy |
3,580,668
+168,069
| +5% | +$1.2M | 0.01% | 1200 |
|
|
2023
Q1 | $20.9M | Buy |
3,412,599
+2,229,060
| +188% | +$15.4M | 0.01% | 1304 |
|
|
2022
Q4 | $7.56M | Sell |
1,183,539
-37,426
| -3% | -$292K | ﹤0.01% | 2427 |
|
|
2022
Q3 | $11.7M | Sell |
1,220,965
-190,222
| -13% | -$2.19M | 0.01% | 1941 |
|
|
2022
Q2 | $15.6M | Sell |
1,411,187
-961,220
| -41% | -$12.6M | 0.01% | 1543 |
|
|
2022
Q1 | $39.5M | Buy |
2,372,407
+2,042,116
| +618% | +$31.6M | 0.02% | 839 |
|
|
2021
Q4 | $6.3M | Buy |
+330,291
| New | +$7.27M | ﹤0.01% | 2658 |
|
|
2021
Q2 | – | Sell |
-580,977
| Closed | -$15.1M | – | 6772 |
|
|
2021
Q1 | $18.4M | Buy |
580,977
+403,549
| +227% | +$16.7M | 0.01% | 1165 |
|
|
2020
Q4 | $8.23M | Sell |
177,428
-634,217
| -78% | -$25.2M | 0.01% | 1955 |
|
|
2020
Q3 | $26.7K | Buy |
811,645
+224,136
| +38% | +$6.87M | 0.03% | 627 |
|
|
2020
Q2 | $16.1M | Buy |
587,509
+429,579
| +272% | +$14.1M | 0.02% | 881 |
|
|
2020
Q1 | $4.73M | Buy |
+157,930
| New | +$4.19M | 0.01% | 1370 |
|
|
2019
Q4 | – | Sell |
-406,526
| Closed | -$9.25M | – | 4413 |
|
|
2019
Q3 | $7.4M | Buy |
+406,526
| New | +$8.99M | 0.01% | 1499 |
|
|
2019
Q2 | – | Sell |
-18,407
| Closed | -$277K | – | 4239 |
|
|
2019
Q1 | $175K | Buy |
+18,407
| New | +$179K | ﹤0.01% | 3767 |
|
|
2018
Q4 | – | Sell |
-60,387
| Closed | -$679K | – | 3942 |
|
|
2018
Q3 | $679K | Sell |
60,387
-652,535
| -92% | -$9.26M | ﹤0.01% | 3078 |
|
|
2018
Q2 | $9.13M | Buy |
712,922
+202,558
| +40% | +$2.96M | 0.01% | 1383 |
|
|
2018
Q1 | $8.63M | Sell |
510,364
-139,287
| -21% | -$2.11M | 0.01% | 1432 |
|
|
2017
Q4 | $5.2M | Sell |
649,651
-1,431,829
| -69% | -$11.5M | 0.01% | 1725 |
|
|
2017
Q3 | $16.1M | Buy |
2,081,480
+1,652,045
| +385% | +$10.5M | 0.02% | 916 |
|
|
2017
Q2 | $3.16M | Buy |
429,435
+416,435
| +3,203% | +$2.65M | 0.01% | 1790 |
|
|
2017
Q1 | $97K | Sell |
13,000
-81,828
| -86% | -$600K | ﹤0.01% | 3330 |
|
|
2016
Q4 | $659K | Buy |
+94,828
| New | +$653K | ﹤0.01% | 2511 |
|
|
2016
Q3 | – | Sell |
-154,631
| Closed | -$1.25M | – | 3420 |
|
|
2016
Q2 | $1.25M | Buy |
154,631
+117,838
| +320% | +$740K | ﹤0.01% | 2031 |
|
|
2016
Q1 | $187K | Buy |
36,793
+6,197
| +20% | +$33.9K | ﹤0.01% | 2972 |
|
|
2015
Q4 | $236K | Buy |
+30,596
| New | +$212K | ﹤0.01% | 3020 |
|
|
2015
Q3 | – | Sell |
-13,152
| Closed | -$121K | – | 3588 |
|
|
2015
Q2 | $121K | Sell |
13,152
-14,958
| -53% | -$167K | ﹤0.01% | 3136 |
|
|
2015
Q1 | $340K | Buy |
+28,110
| New | +$317K | ﹤0.01% | 2967 |
|
Other funds holding IOVA
MFM
PAI
Israel Englander's IOVA Position: Q2 2026 in Review
Israel Englander reduced its Iovance Biotherapeutics (IOVA) stake by 9.4% in Q2 2026, selling an estimated $3.38M and leaving 8,525,919 shares worth $35.5M. The position accounts for 0.01% of the portfolio, ranked #1146.
Israel Englander first reported a position in IOVA in Q1 2015 and has held it in 39 quarters since. The position peaked at $39.5M in Q1 2022. 290 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.
- Israel Englander held 8,525,919 shares of Iovance Biotherapeutics worth $35.5M as of Q2 2026.
- Israel Englander sold 888,373 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.38M.
- Iovance Biotherapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1146 holding.
- Israel Englander first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 39 quarters since.
- Israel Englander's Iovance Biotherapeutics position peaked at $39.5M in Q1 2022.
- 290 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.